Kellie D. Nance

1.7k citations

26 papers · 1.2k · 1 hit paper · h-index 16

Impact in

Molecular Biology top 10%
- RNA modifications and cancer
- RNA and protein synthesis mechanisms
- Receptor Mechanisms and Signaling
- RNA Research and Splicing
- RNA Interference and Gene Delivery
- Nicotinic Acetylcholine Receptors Study
Cancer Research
- Cancer-related molecular mechanisms research

Papers in

Cellular and Molecular Neuroscience 9
- Neuroscience and Neuropharmacology Research 9
Molecular Biology 24
- Receptor Mechanisms and Signaling 12
- RNA modifications and cancer 7
- RNA and protein synthesis mechanisms 6
- RNA Research and Splicing 5
- Ion channel regulation and function 2
- Chemical Synthesis and Analysis 2

Co-authors: Jordan L. Meier (6 shared papers)Craig W. Lindsley (13 shared papers)David Bartee (1 shared paper)Carrie K. Jones (7 shared papers)P. Jeffrey Conn (8 shared papers)Colleen Marie Niswender (8 shared papers)Hyekyung P. Cho (6 shared papers)Anna Louise Blobaum (6 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (6 papers)ACS Chemical Neuroscience (4 papers)ACS Medicinal Chemistry Letters (3 papers)Journal of the American Chemical Society (2 papers)Cell chemical biology (2 papers)
Partner nations: United States Israel Canada

In The Last Decade

Kellie D. Nance

26 papers receiving 1.2k citations

Kellie D. Nance's Hit Papers

align trajectories log scale

Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines 2021 · 324 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2021 ACS Central Science

Peers

Countries citing papers authored by Kellie D. Nance

Since Specialization

Citations

This map shows the geographic impact of Kellie D. Nance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kellie D. Nance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kellie D. Nance more than expected).

Fields of papers citing papers by Kellie D. Nance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kellie D. Nance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kellie D. Nance. The network helps show where Kellie D. Nance may publish in the future.

Co-authors

The 25 scholars most cited alongside Kellie D. Nance, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kellie D. Nance Line = papers co-authored together Kellie D. Nance links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines ACS Central Science ·Kellie D. Nance, Jordan L. Meier Hit paper breakdown →	2021	324
2	Dynamic RNA acetylation revealed by quantitative cross-evolutionary mapping Nature ·Aldema Sas‐Chen, Justin M. Thomas, Donna Matzov, Masato Taoka, Kellie D. Nance, Ronit Nir, Keri M. Bryson, Ran Shachar	2020	259
3	A Chemical Signature for Cytidine Acetylation in RNA Journal of the American Chemical Society ·Justin M. Thomas, Chloe A. Briney, Kellie D. Nance, Jeffrey E. López, Abigail L. Thorpe, Stephen D. Fox, Marie‐Line Bortolin‐Cavaillé, Aldema Sas‐Chen	2018	93
4	Site-Specific Synthesis of N 4 -Acetylcytidine in RNA Reveals Physiological Duplex Stabilization Journal of the American Chemical Society ·David Bartee, Kellie D. Nance, Jordan L. Meier	2022	53
5	A Novel M 1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity ACS Chemical Neuroscience ·Jerri M. Rook, Jeanette L. Bertron, Hyekyung P. Cho, Pedro M. García-Barrantes, Sean P. Moran, James Maksymetz, Kellie D. Nance, Jonathan W. Dickerson	2018	52
6	Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia ACS Medicinal Chemistry Letters ·Michael R. Wood, Meredith J. Noetzel, Bruce J. Melancon, Michael S. Poslusney, Kellie D. Nance, Miguel Hurtado, Vincent B. Luscombe, Rebecca L. Weiner	2016	49
7	Diverse Effects on M 1 Signaling and Adverse Effect Liability within a Series of M 1 Ago-PAMs ACS Chemical Neuroscience ·Jerri M. Rook, Masahito Abe, Hyekyung P. Cho, Kellie D. Nance, Vincent B. Luscombe, Jeffrey J. Adams, Jonathan W. Dickerson, Daniel H. Remke	2016	46
8	Discovery of ( S )-2-Cyclopentyl- N -((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1 H -pyrrido[3,4- b ]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM) Journal of Medicinal Chemistry ·Lindsey C. Morris, Kellie D. Nance, Patrick R. Gentry, Emily Days, C. David Weaver, Colleen Marie Niswender, Analisa D. Thompson, Carrie K. Jones	2014	38
9	Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354 Bioorganic & Medicinal Chemistry Letters ·Wandong Wen, Summer E. Young, Matthew Thomas Duvernay, M. Schulte, Kellie D. Nance, Bruce J. Melancon, Julie L. Engers, Charles W. Locuson	2014	37
10	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1PAM VU6004256 ACS Chemical Neuroscience ·Michael D. Grannan, Catharine A. Mielnik, Sean P. Moran, Robert W. Gould, Jacob Ball, Zhuoyan Lu, Michael Bubser, Amy J. Ramsey	2016	36
11	Design of Fluorine-Containing 3,4-Diarylfuran-2(5 H )-ones as Selective COX-1 Inhibitors ACS Medicinal Chemistry Letters ·Md. Jashim Uddin, Anna V. Elleman, Kebreab Ghebreselasie, Cristina K. Daniel, Brenda C. Crews, Kellie D. Nance, Tamanna Huda, Lawrence J. Marnett	2014	33
12	Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA Cell chemical biology ·Kellie D. Nance, Supuni Thalalla Gamage, Md Masud Alam, Acong Yang, Michaella J. Levy, Courtney N. Link, Laurence A. Florens, Michael P. Washburn	2021	28
13	Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine Acetylation ACS Medicinal Chemistry Letters ·Jonathan H. Shrimp, Yihang Jing, Supuni Thalalla Gamage, Kathryn M. Nelson, Joseph Han, Keri M. Bryson, David C. Montgomery, Justin M. Thomas	2020	28
14	Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies Bioorganic & Medicinal Chemistry Letters ·Kevin M. McGowan, Kellie D. Nance, Hykeyung P. Cho, Thomas M. Bridges, P. Jeffrey Conn, Carrie K. Jones, Craig W. Lindsley	2017	27
15	A Systems Chemoproteomic Analysis of Acyl-CoA/Protein Interaction Networks Cell chemical biology ·Michaella J. Levy, David C. Montgomery, Mihaela E. Sardiu, José L. Montaño, Sarah E. Bergholtz, Kellie D. Nance, Abigail L. Thorpe, Stephen D. Fox	2019	23
16	Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology Bioorganic & Medicinal Chemistry Letters ·Bruce J. Melancon, Michael R. Wood, Meredith J. Noetzel, Kellie D. Nance, Eileen M. Engelberg, Changho Han, Atin Lamsal, Sichen Chang	2017	22
17	Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes Bioorganic & Medicinal Chemistry Letters ·Alexander R. Geanes, Hykeyung P. Cho, Kellie D. Nance, Kevin M. McGowan, P. Jeffrey Conn, Carrie K. Jones, Jens Meiler, Craig W. Lindsley	2016	16
18	Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold ACS Chemical Neuroscience ·Aaron M. Bender, Hyekyung P. Cho, Kellie D. Nance, Kaelyn S. Lingenfelter, Vincent B. Luscombe, Patrick R. Gentry, Karl R. Voigtritter, Alice E. Berizzi	2018	13
19	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core Journal of Medicinal Chemistry ·Kellie D. Nance, Emily Days, C. David Weaver, Anastasia Coldren, Tiffany D. Farmer, Hyekyung P. Cho, Colleen Marie Niswender, Anna Louise Blobaum	2017	13
20	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core Bioorganic & Medicinal Chemistry Letters ·Jeanette L. Bertron, Hyekyung P. Cho, Pedro M. García-Barrantes, Joseph D. Panarese, James M. Salovich, Kellie D. Nance, Darren W. Engers, Jerri M. Rook	2018	11

About Kellie D. Nance

Kellie D. Nance is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology, Computational Theory and Mathematics, Endocrinology, Diabetes and Metabolism and Biological Psychiatry, having authored 26 papers that have together received 1.2k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (12 papers), Neuroscience and Neuropharmacology Research (9 papers), RNA modifications and cancer (7 papers), RNA and protein synthesis mechanisms (6 papers), RNA Research and Splicing (5 papers), Computational Drug Discovery Methods (4 papers), Ion channel regulation and function (2 papers) and Chemical Synthesis and Analysis (2 papers). The work is most often cited by research in Molecular Biology (999 citations), Cancer Research (163 citations), Cellular and Molecular Neuroscience (197 citations), Infectious Diseases (81 citations) and Organic Chemistry (100 citations). Kellie D. Nance has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Jordan L. Meier, Craig W. Lindsley, David Bartee, Carrie K. Jones, P. Jeffrey Conn, Colleen Marie Niswender, Hyekyung P. Cho, Anna Louise Blobaum, Stephen D. Fox and Abigail L. Thorpe. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Chemical Neuroscience, ACS Medicinal Chemistry Letters, Journal of the American Chemical Society and Cell chemical biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Kellie D. Nance

Impact in

Papers in i

In The Last Decade

Kellie D. Nance

Kellie D. Nance's Hit Papers

Peers

Countries citing papers authored by Kellie D. Nance

Fields of papers citing papers by Kellie D. Nance

All Works

About Kellie D. Nance

Explore authors with similar magnitude of impact

Papers in